This type arises from the urothelial lining, similar to bladder cancer. It may coexist with bladder tumors and requires careful evaluation of the entire urinary tract.
Often associated with chronic inflammation, urethral strictures, or infections. This subtype is commonly seen in the distal (anterior) urethra.
A rare subtype that develops from glandular cells. It requires specialized management based on its unique biological behavior.
The histological subtype plays a crucial role in determining treatment strategy, prognosis, and the need for chemotherapy or radiation therapy.
While no single cause has been identified, several factors increase susceptibility:
Chronic irritation of the urethral lining plays a significant role. Persistent urinary symptoms should always be evaluated rather than assumed to be benign.
Symptoms often resemble common urinary disorders, which may delay diagnosis. Warning signs include:
In advanced cases, pelvic pain or obstructive urinary symptoms may occur. Any persistent or unexplained symptom should prompt specialist consultation.
Accurate diagnosis and staging form the foundation of effective treatment. Because urethral cancer is rare, evaluation must be systematic and thorough.
A detailed examination assesses local tumor extent and lymph node involvement.
A camera is inserted through the urethra to visualize the tumor and obtain tissue for histopathological confirmation.
MRI helps determine depth of invasion and involvement of surrounding organs.
CT scan of the chest, abdomen, and pelvis is used to detect distant spread.
Reserved for selected advanced cases to evaluate metastatic disease.
Suspicious inguinal lymph nodes may require biopsy for accurate staging.
Staging determines whether the disease is localized, locally advanced, or metastatic. Treatment planning is based on stage to ensure optimal outcomes.
Management depends on tumor location, stage, histology, lymph node involvement, and overall patient health. Treatment is individualized to achieve optimal cancer control while preserving function whenever possible.
Surgery is the cornerstone for most localized and locally advanced urethral cancers. Procedures may include:
The goal is complete tumor removal with clear margins while preserving urinary and sexual function whenever oncologically safe.
Chemotherapy may be used before surgery (neoadjuvant), after surgery (adjuvant), or as primary treatment in metastatic disease.
Multimodality therapy often improves survival outcomes in advanced urethral cancer.
Radiation therapy may be considered as definitive treatment in selected early-stage cases, as adjuvant therapy, or for palliation in metastatic disease.
The choice between surgery and radiation depends on tumor location, stage, and patient preference.
Treatment planning for urethral cancer focuses not only on disease control but also on preserving overall well-being and quality of life.
Due to its rarity, urethral cancer requires specialized care. Timely diagnosis and expert treatment significantly improve outcomes.
Dr. Lovedeep Singh Chauhan is a Consultant Surgical Oncologist in punjab at Max Super Speciality Hospital, Mohali with specialized training in complex oncologic surgeries. His background at Tata Memorial Hospital—one of India’s leading cancer institutes—ensures adherence to internationally accepted treatment protocols.
Each case is evaluated in detail, and treatment plans are individualized rather than standardized to ensure the best possible outcomes.
Cancer treatment is rarely one-dimensional. Urethral cancer management may involve:
At Max Super Speciality Hospital, Mohali, cases are discussed in tumor board meetings to ensure comprehensive planning.
Post-treatment monitoring is crucial to detect recurrence early.
Structured follow-up ensures long-term safety and quality of life.
You should consult a specialist if you experience:
Early evaluation significantly improves the chances of successful treatment.